Pharmacological characterization of serotonin receptor subtypes involved in vasopressin and plasma renin activity responses to serotonin agonists.

[1]  D. Murphy,et al.  β-Endorphin responses to different serotonin agonists: involvement of corticotropin-releasing hormone, vasopressin and direct pituitary action , 1990, Brain Research.

[2]  J. Doane,et al.  Quipazine Increases Renin Release by a Peripheral Hemodynamic Mechanism , 1990, Journal of cardiovascular pharmacology.

[3]  D. Murphy,et al.  Serotonin agonists cause parallel activation of the sympathoadrenomedullary system and the hypothalamo-pituitary-adrenocortical axis in conscious rats. , 1989, Endocrinology.

[4]  D. Murphy,et al.  Different serotonin receptors mediate blood pressure, heart rate, plasma catecholamine and prolactin responses to m-chlorophenylpiperazine in conscious rats. , 1989, The Journal of pharmacology and experimental therapeutics.

[5]  G. Kennett,et al.  Evidence that mCPP may have behavioural effects mediated by central 5‐HT1C receptors , 1988, British journal of pharmacology.

[6]  L. D. van de Kar,et al.  Neuropharmacological characterization of serotoninergic stimulation of vasopressin secretion in conscious rats. , 1988, Neuroendocrinology.

[7]  D. Hoyer.  Molecular pharmacology and biology of 5-HT1C receptors. , 1988, Trends in pharmacological sciences.

[8]  R. Alper,et al.  Activation of serotonin2 (5-HT2) receptors by quipazine increases arterial pressure and renin secretion in conscious rats. , 1987, The Journal of pharmacology and experimental therapeutics.

[9]  D. Murphy,et al.  M-chlorophenylpiperazine increases blood pressure and heart rate in pithed and conscious rats. , 1987, Life sciences.

[10]  D. Murphy,et al.  Long‐term imipramine treatment enhances locomotor and food intake suppressant effects of m‐chlorophenylpiperazine in rats , 1987, British journal of pharmacology.

[11]  P. Conn,et al.  Relative efficacies of piperazines at the phosphoinositide hydrolysis-linked serotonergic (5-HT-2 and 5-HT-1c) receptors. , 1987, The Journal of pharmacology and experimental therapeutics.

[12]  L. D. van de Kar,et al.  Differential effects of serotonin (5-HT1A and 5-HT2) agonists and antagonists on renin and corticosterone secretion. , 1987, Neuroendocrinology.

[13]  L. Steardo,et al.  Vasopressin release after enhanced serotonergic transmission is not due to activation of the peripheral renin-angiotensin system , 1986, Brain Research.

[14]  A. Sved.  Peripheral pressor systems in hypertension caused by nucleus tractus solitarius lesions. , 1986, Hypertension.

[15]  D. Reis,et al.  Vasopressin contributes to hypertension caused by nucleus tractus solitarius lesions. , 1985, Hypertension.

[16]  R. Fuller,et al.  Antagonism of vascular serotonin receptors by m-chlorophenylpiperazine and m-trifluoromethylphenylpiperazine. , 1983, Life sciences.

[17]  J. Takahara,et al.  The effect of serotonin agonist 1-(trifluoromethylphenyl)-piperazine on corticotropin releasing factor and arginine vasopressin in rat hypothalamic nuclei. , 1982, Endocrinologia japonica.

[18]  D. Hoyer.  Functional correlates of serotonin 5-HT1 recognition sites. , 1988, Journal of receptor research.

[19]  R. Glennon,et al.  Iodine-125 labeled 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane: an iodinated radioligand that specifically labels the agonist high-affinity state of 5-HT2 serotonin receptors , 1988 .